Figure 3.

Blockade of Leptin Actions in DIO Mice Reduces Elevated BP and HR

(A–C) (A) Percentage change in HR, (B) SBP, and (C) DBP over a 5 day treatment period with either leptin antibody or vehicle (IgG control). Student’s t test, n = 4–8.

(D) Percentage daily change in body weight of DIO mice before and during 5 days of treatment and posttreatment of leptin antibody or vehicle (IgG control). Two-way ANOVA, Bonferroni post hoc test. n = 4–8.

(E) Daily change in HR (BPM) in DIO mice treated LV with aCSF or leptin receptor antagonist (LRA). Two way ANOVA, Bonferroni post hoc, n = 4-6

(F) Total 24hr HR(BPM) after 7 days of LRA treatment in DIO mice compared to lean and DIO mice baselines. t test paired (DIO baseline versus LRA), unpaired t test. n = 6–37.

(G) Daily change in SBP (mmHg) from baseline in DIO mice treated in the LV with aCSF or LRA. Two-way ANOVA, Bonferroni post hoc test, n = 4–6.

(H) Total 24 hr SBP (mmHg) after 7 days of LRA treatment in DIO mice compared to the baselines of lean and DIO mice. t test paired (DIO baseline versus LRA), unpaired t test. n = 6–37.

(I) Daily change in DBP (mmHg) in DIO mice treated with LVaCSF or LRA. Two-way ANOVA, Bonferroni post hoc, n = 4–6.

(J) Total 24 hr DBP (mmHg) after 7 days of LRA in DIO mice compared to the baseline measurements of lean and DIO mice. t test paired (DIO baseline versus LRA), unpaired t test. n = 6–37.

(K) Average food intake over the 7 day treatment period of LVaCSF (control) or LRA DIO mice. t test, n = 4–6.

Values represent mean ± SEM. ^∗p < 0.05, ^∗∗p < 0.01, and ^∗∗∗p < 0.001. See also Figure S2.